23341158|t|Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics.
23341158|a|OBJECTIVE: To review the evidence for the efficacy and safety of pharmacologic agents for the treatment of depressive and psychotic disorders in patients with HIV infection and to provide clinical considerations for the treatment of depression and psychosis in these patients. DATA SOURCES: PubMed was searched for articles published between 1966 and August 1, 2012, using the search terms antiretrovirals, HIV, AIDS, depression, psychosis, schizophrenia, antidepressant, antipsychotic, and individual drug names (fluoxetine, sertraline, paroxetine, citalopram, escitalopram, venlafaxine, duloxetine, mirtazapine, bupropion, haloperidol, perphenazine, fluphenazine, aripiprazole, asenapine, clozapine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone). STUDY SELECTION AND DATA EXTRACTION: For the purposes of evaluating efficacy data, we limited our selection to randomized placebo-controlled or active comparator-controlled trials for agents that have been used for depression and psychosis in HIV-infected patients. DATA SYNTHESIS: We found 11 studies for depression treatment and 1 study for psychosis treatment that met our inclusion and exclusion criteria. Selective serotonin reuptake inhibitors (SSRIs; especially fluoxetine) and tricyclic antidepressants appear to be effective in treating depressive symptoms in patients with HIV infection without affecting immune status. Testosterone, stimulants, and dehydroepiandrosterone may also be effective in subsyndromal depression; however, studies on these agents in general were limited by small sample size. There are limited data for antipsychotics, with the only controlled study found for haloperidol and chlorpromazine used for AIDS delirium. Drug-drug interactions and potentiation of metabolic syndrome are concerns for the combined use of antidepressants and antipsychotics with antiretrovirals. CONCLUSIONS: Larger controlled studies are needed to validate the current findings as well as expand knowledge for non-SSRI antidepressants and second-generation antipsychotics for use in HIV-infected patients.
23341158	34	42	patients	Species	9606
23341158	48	51	HIV	Disease	MESH:D015658
23341158	56	77	psychiatric disorders	Disease	MESH:D001523
23341158	231	265	depressive and psychotic disorders	Disease	MESH:D000341
23341158	269	277	patients	Species	9606
23341158	283	296	HIV infection	Disease	MESH:D015658
23341158	357	367	depression	Disease	MESH:D003866
23341158	372	381	psychosis	Disease	MESH:D011618
23341158	391	399	patients	Species	9606
23341158	531	534	HIV	Disease	MESH:D015658
23341158	536	540	AIDS	Disease	MESH:D000163
23341158	542	552	depression	Disease	MESH:D003866
23341158	554	563	psychosis	Disease	MESH:D011618
23341158	565	578	schizophrenia	Disease	MESH:D012559
23341158	638	648	fluoxetine	Chemical	MESH:D005473
23341158	650	660	sertraline	Chemical	MESH:D020280
23341158	662	672	paroxetine	Chemical	MESH:D017374
23341158	674	684	citalopram	Chemical	MESH:D015283
23341158	686	698	escitalopram	Chemical	MESH:D000089983
23341158	700	711	venlafaxine	Chemical	MESH:D000069470
23341158	713	723	duloxetine	Chemical	MESH:D000068736
23341158	725	736	mirtazapine	Chemical	MESH:D000078785
23341158	738	747	bupropion	Chemical	MESH:D016642
23341158	749	760	haloperidol	Chemical	MESH:D006220
23341158	762	774	perphenazine	Chemical	MESH:D010546
23341158	776	788	fluphenazine	Chemical	MESH:D005476
23341158	790	802	aripiprazole	Chemical	MESH:D000068180
23341158	804	813	asenapine	Chemical	MESH:C522667
23341158	815	824	clozapine	Chemical	MESH:D003024
23341158	826	837	iloperidone	Chemical	MESH:C081732
23341158	839	849	lurasidone	Chemical	MESH:D000069056
23341158	851	861	olanzapine	Chemical	MESH:D000077152
23341158	863	875	paliperidone	Chemical	MESH:D000068882
23341158	877	887	quetiapine	Chemical	MESH:D000069348
23341158	889	900	risperidone	Chemical	MESH:D018967
23341158	902	913	ziprasidone	Chemical	MESH:C092292
23341158	1131	1141	depression	Disease	MESH:D003866
23341158	1146	1155	psychosis	Disease	MESH:D011618
23341158	1159	1171	HIV-infected	Disease	MESH:D015658
23341158	1172	1180	patients	Species	9606
23341158	1222	1232	depression	Disease	MESH:D003866
23341158	1259	1268	psychosis	Disease	MESH:D011618
23341158	1385	1395	fluoxetine	Chemical	MESH:D005473
23341158	1462	1481	depressive symptoms	Disease	MESH:D003866
23341158	1485	1493	patients	Species	9606
23341158	1499	1512	HIV infection	Disease	MESH:D015658
23341158	1546	1558	Testosterone	Chemical	MESH:D013739
23341158	1576	1598	dehydroepiandrosterone	Chemical	MESH:D003687
23341158	1624	1647	subsyndromal depression	Disease	MESH:D003866
23341158	1812	1823	haloperidol	Chemical	MESH:D006220
23341158	1828	1842	chlorpromazine	Chemical	MESH:D002746
23341158	1852	1865	AIDS delirium	Disease	MESH:D000163
23341158	1910	1928	metabolic syndrome	Disease	MESH:D024821
23341158	2211	2223	HIV-infected	Disease	MESH:D015658
23341158	2224	2232	patients	Species	9606
23341158	Negative_Correlation	MESH:D002746	MESH:D000163
23341158	Negative_Correlation	MESH:D005473	MESH:D015658
23341158	Negative_Correlation	MESH:D013739	MESH:D003866
23341158	Negative_Correlation	MESH:D005473	MESH:D003866
23341158	Negative_Correlation	MESH:D003687	MESH:D003866
23341158	Negative_Correlation	MESH:D006220	MESH:D000163

